Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.
This long awaited drug approval is the first rosacea drug approved this year and Harper talks how it works, its potential as a first line treatment, and much more in this interview.
Video
Comments on the Epsolay FDA Approval for Rosacea
Author(s):
Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.
Julie Harper, MD, of the Dermatology and Skin Care Center of Birmingham, Alabama, sits down to talk the approval of the 5% encapsulated benzoyl peroxide (E-BPO) cream (Epsolay; Sol-Gel Technologies Ltd and Galderma) that was just recently approved for the treatment of inflammatory lesions of rosacea (papulopustular rosacea or PPR) in adult patients.
This long awaited drug approval is the first rosacea drug approved this year and Harper talks how it works, its potential as a first line treatment, and much more in this interview.
FDA Approves Journey Medical’s DFD-29 for Rosacea
New TRoSA Scale Standardizes Telangiectasia Severity in Rosacea
Ferulic Acid Effective in Treating Papulopustular Rosacea
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved
Rosacea Treatment: Letting the Patient Lead the Way
Insights on Acne and Rosacea Treatment with James Del Rosso, DO
FDA Approves Journey Medical’s DFD-29 for Rosacea
New TRoSA Scale Standardizes Telangiectasia Severity in Rosacea
Ferulic Acid Effective in Treating Papulopustular Rosacea
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved
Rosacea Treatment: Letting the Patient Lead the Way
Insights on Acne and Rosacea Treatment with James Del Rosso, DO